NJ-OPENLEGACY
OpenLegacy , which delivers monolithic mainframe system interfaces as cloud-native building blocks of innovation, today announced OL Hub, the only modernization platform that supports generation of services from all types of core assets with the speed and simplicity of cloud development.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211005005195/en/
Despite the explosive growth of the global low-code and no-code market for application development, integration of core assets have largely been left out. OpenLegacy’s digital-driven integration OL Hub allows companies to build new services leveraging core systems at the same speed they build digital systems. By enabling the reuse of legacy assets in new combinations quickly and seamlessly without the maintenance costs of low-level APIs or enterprise service bus (ESB), OL Hub can be easily deployed regardless of a company’s digital platform.
“OL Hub helps businesses from financial institutions to insurance providers dramatically shorten the time to market for new digital services. Business leaders can quickly adapt to meet evolving business needs,” explains OpenLegacy CEO Romi Stein. “Enterprises easily build business-level APIs from core assets with OL Hub. This enhanced flexibility, simplifies the way API designers build services that reference monolithic legacy systems, and automates the representative creation and cataloging of previous interfaces with the ease of a cloud-native app.”
“OpenLegacy Hub represents a completely new way to design cloud-native services from core assets,” states OpenLegacy Chief Product Officer Zeev Avidan. “OL Hub supports the creation of low-, no-, and full-code services in a variety of deployment options including .NET with C#, Java, node.JS, microservices or serverless both on cloud and on-premise. Through its user-friendly interface, the platform simplifies core asset integration and enables equitable enterprise-wide access to digital resources with multiple entry points for independent software vendors (ISVs) to access those assets.”
The OL Hub Platform is built from OpenLegacy’s award-winning integration technology. Hub supports the automation of the entire integration process to help companies achieve their digital journey at speed. OL Hub is now available for cloud-based free trials. Schedule a remote-based product demo here .
About OpenLegacy
OpenLegacy’s Digital-Driven Integration enables organizations with legacy systems to release new digital services faster and more efficiently than ever before. It connects directly to even the most complex legacy systems, bypassing the need for extra layers of technology. It then automatically generates APIs in minutes, rapidly integrating those assets into new and exciting innovations. Finally, it deploys them as standard microservices or serverless functions, giving organizations speed and flexibility while drastically cutting costs and resources. With OpenLegacy, industry leading companies release new apps, features, and updates in days instead of months, enabling them to truly become digital to the core. Learn why leading companies choose OpenLegacy at openlegacy.com
, and follow us on Twitter
or LinkedIn
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211005005195/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LabGenius Therapeutics Announces Poster Presentation at the ESMO Immuno-Oncology Congress 202513.11.2025 01:00:00 CET | Press release
LabGenius Therapeutics (“LabGenius”), a drug discovery company combining artificial intelligence (AI) and high-throughput experimentation to advance next-generation multispecific antibodies for solid tumours, today announced a scientific poster will be presented at the ESMO Immuno-Oncology Congress 2025, being held December 10 - 12, 2025, at the Queen Elizabeth II Centre in London, United Kingdom. LabGenius’ presentation will debut the pre-clinical in vivo efficacy (>90% tumour growth inhibition) and tolerability data for their lead asset, a highly tumour selective bispecific T-cell engager (TCE). Poster Presentation Details Title Novel Selectivity-Enhanced Bispecific T-cell Engager Utilises Avidity to Overcome On-target, Off-tumour Toxicity Date and time Wednesday, December 10, 2025, 08:00 (GMT) Poster number 309P Location The Churchill Room, Queen Elizabeth II Centre, London Bispecific TCE Overview For the selected target, LabGenius has developed a selectivity-enhanced TCE. The compa
VeriSilicon and Google Jointly Launch Open-Source Coral NPU IP13.11.2025 01:00:00 CET | Press release
Targeting edge LLM applications, accelerating edge AI ecosystem development VeriSilicon (688521.SH) recently announced the joint launch of the Coral NPU IP with Google, targeting always-on, ultra-low-energy edge Large Language Model (LLM) applications. The IP is based on Google’s foundational research in open machine learning compilers and enhanced with AI security features, providing developers with a unified open-source platform to build a robust edge AI ecosystem. The Coral NPU is built on the open RISC-V instruction set architecture, featuring native tensor processing capabilities, supporting mainstream machine learning frameworks such as JAX, PyTorch, and TensorFlow Lite (TFLite), and utilizing open-standard tools like Multi-Level Intermediate Representation (MLIR) from the Low Level Virtual Machine (LLVM) project for compiler infrastructure. It is designed for always-on, ultra-low-energy edge AI applications, particularly for wearable devices and ambient sensing systems. The Cora
Indero Announces Breakthrough Method for Early-Phase Evaluation of Topical Drugs Using Quantitative Gene Expression13.11.2025 00:00:00 CET | Press release
Indero is proud to announce the successful completion of an internally funded study that introduces a novel approach to evaluating topical new chemical entities (NCE) in early-phase clinical research. This innovative method leverages quantitative gene expression analysis to assess drug efficacy rapidly and cost effectively. Dr. Robert Bissonnette, Executive Chairman and Founder of Indero, who initiated and led the study, shared his excitement about the results: “Our goal was to rethink how to study topical drugs in early phase studies. The results of this study demonstrate that microdosing for only 3 days can provide meaningful efficacy signals. Within just 24 hours, we observed alterations in gene expression after applying a microdose of mid-potency corticosteroid on the skin of patients. By 72 hours, Th2, Th22 and Th17-specific biomarkers were significantly reduced. This outcome is exactly what we hoped for and opens the door to faster, smarter drug development strategies, demonstrat
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem samarbejde med VaporVM12.11.2025 23:54:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for digital transformation og cybersikkerhed med tilføjelsen af samarbejdspartneren VaporVM, der er et cloud-native teknologifirma med hovedsæde i Dubai. VaporVM, der blev grundlagt i 2017, hjælper globale virksomheder med at navigere i digital transformation gennem integrerede cloud-tjenester, DevOps, cybersikkerhed, datavidenskab og modernisering af applikationer. Med fokus på skalerbarhed og hurtigere lanceringer arbejder firmaet med Fortune 500-virksomheder og udnytter deres ekspertise og automatisering til at effektivisere it-drift og fremskynde digitale resultater. "Hos VaporVM brænder vi for at hjælpe virksomheder med ikke bare at tage nye teknologier til sig, men også at gentænke, hvad der kan lade sig gøre, når de bruges til at skabe reel forandring," siger Aqeel Asim, der er CEO og grundlægger af VaporVM. "Samarbejdet med Andersen Consulting giver os mulighed for at løfte vores mission til et globalt niveau – så vi kan bringe
Valorem Reply recognized as Winner of 2025 Microsoft Inclusion Changemaker Partner of the Year12.11.2025 21:30:00 CET | Press release
Valorem Reply, the Reply Group company specializing in Microsoft technologies and AI-driven, cloud-native solutions, announced today it has won the 2025 Microsoft Inclusion Changemaker Partner of the Year Award. The company was honored among a global field of top Microsoft partners for demonstrating excellence in innovation and implementation of customer solutions based on Microsoft technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251112917859/en/ The Inclusion Changemaker Partner of the Year Award celebrates partners that lead with inclusive design, accessibility, and innovation to help customers and communities achieve more. “We’re proud of Valorem Reply for earning this recognition,” said Filippo Rizzante, CTO at Reply. “Their work exemplifies our shared commitment to inclusion and to using technology as a catalyst for opportunity and meaningful change. This award reflects the dedication and creativity of the Va
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom